Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$163.58M

FY 2025 · Annual

Investing Cash Flow

-$138,000.00

FY 2025 · Annual

Financing Cash Flow

-$139,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$244.1M
+ D&A$895.0K
+ Stock-Based Comp$37.6M
+ Deferred Tax$43.2M
- Working Capital-$4.2M
+ Other Non-Cash$2.9M
= Operating Cash Flow-$163.6M
- Capex-$138.0K
= Free Cash Flow-$163.7M

Analysis

FY2025 free cash flow is -$163.7M. FCF conversion is 67.1% of net income. Operating cash flow was -$163.6M, with capex of -$138.0K. The largest bridge item is Deferred Tax at $43.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
3Initial statement of beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

Does PRTA generate free cash flow?

Prothena Corporation plc (PRTA) generated -$163.72M of free cash flow in fiscal 2025.

How much operating cash flow does PRTA produce?

Operating cash flow was -$163.58M, before capital expenditures of $138,000.00.